Trials / Unknown
UnknownNCT05191342
Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis
The Expression of Proprotein Convertase Subtilisin Kexin 9 in Patients With Rheumatoid Arthritis Combined Atrial Fibrillation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 75 (estimated)
- Sponsor
- First Affiliated Hospital of Harbin Medical University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
Rheumatoid arthritis (RA) has been proved to increase the incidence of atrial fibrillation (AF) with persistent systemic inflammation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been found to enhance the production of pro-inflammatory cytokines. Therefore, we performed the present study to observe the expression and significance of proprotein convertase subtilisin kexin 9 (PCSK9) in patients with RA combined atrial fibrillation.
Detailed description
Atrial fibrillation (AF), the most common clinically relevant arrhythmia, is an important contributor to population morbidity and mortality. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, which affects approximately 1% of the population. Increasing studies demonstrated that RA had a positive correlation with increased cardiovascular diseases. Increasing studies showed that the prevalence of AF is significantly higher in RA patients than in the general population. Recently, some studies indicated that proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes inflammatory by regulating macrophage secretion of inflammatory cytokines, inducing C-reaction protein (CRP), interleukin (IL)-6, IL-8, tumor necrosis factor-α (TNF-α) and so on. However, the levels of PCSK9 in atrial fibrillation patients with rheumatoid arthritis is still unclear. Therefore, the aim of this study was to assess the expression of PCSK9 in patients with RA combined atrial fibrillation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Enzyme-linked immunosorbent assay for PCSK9 | Enzyme-linked immunosorbent assay for plasma PCSK9 |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
- First posted
- 2022-01-13
- Last updated
- 2022-01-13
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05191342. Inclusion in this directory is not an endorsement.